Financing & Shareholding

Categories

Turnover: n/a

Employees: 1 - 10

Region: Baden-Württemberg

Description

The company has developed a method to stop harmful processes in the brain without impairing normal functions. Using a special type of inhibitor, the neurodegenerative effect of certain receptors is suppressed while their positive effect on memory and nerve cell survival is maintained. The company is currently in the preclinical stage.

Contact

Igor Velichkov (Project Manager)

E-Mail Igor.Velichkov@PortusCo.com